Intelligence / Healthtech / New Clinical Trials / Alkermes, Inc.
Alkermes, Inc.
28 Oct 2026: Trial registered · A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 28 Oct 2026
- Title
- A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder
- Conditions
- Major Depressive Disorder (MDD)
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- United States
- Country
- United States
- Reference
- NCT07901179
- Location
- United States
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Alkermes, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from United States
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.